参考文献/References:
[1]金宇,刘晓玲,黄怡丹.免疫球蛋白和自身抗体在乙型肝炎肝硬化发病和进展中的表达及与预后的关系[J].中国现代医学杂志,2023,33(4):56-61.[2]Mak L,Wong D,Pollicino T,et al.Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance[J].Journal of Hepatology,2020,4(1):574-578.[3]Liu Y,May L,Liu X,et al.Developing a sensitive HBV genotyping assay for HBV DNA suppressed patients using both DNA and RNA sequencing[J].Journal of Medical Virology,2020,92(12):37.[4]张玲,郑荣,何三军,等.慢性乙型肝炎患者HBV-DNA载量、肝功能指标与免疫学标志物的相关性研究[J].检验医学与临床,2020,17(22):3348-3350.[5]冯变莹,穆迪,黄平,等.乙肝五项血清标志物、PreS1抗原和HBV-DNA联合检测在老年乙型肝炎患者诊疗中的应用价值研究[J].老年医学与保健,2020,26(4):613-617.[6]Mingjian L,Qianming W,Shidong C,et al.The association of serum immunoglobulin and complement levels and liver fibrosis and inflammation stage in patients with chronic hepatitis B.[J].Journal of Viral Hepatitis,2023,16(1):372-377.[7]王贵强,段钟平,王福生,等.慢性乙型肝炎防治指南(2019年版)[J].实用肝脏病杂志,2020,23(1):9-32.[8]谢宇端,韩艳,高原小雪.荧光定量聚合酶链反应检测慢性乙肝患者HBV DNA的意义[J].标记免疫分析与临床,2020,27(3):513-517,527.[9]邹卓林,谢新生.HBV-DNA定量与乙肝血清标志物联合检测在乙肝中的应用价值分析[J].中国地方病防治杂志,2019,34(6):696-697.[10]周洁,杨梅,赵琦,等.526例慢性乙肝患者不同病期HBV-DNA载量与外周血TBi、TBA、ALB、ALP变化分析[J].贵州医药,2019,43(9):1377-1378.[11]林孟新,苏智军,郭如意,等.乙肝表面抗原联合免疫球蛋白补体检测在肝脏疾病中的临床价值研究[J].中国实用内科杂志,2019,39(9):817-819.[12]陈贤坤,吴翠云.HBsAg及HBV DNA定量检测在慢性乙型肝炎患者不同病程阶段中的应用价值[J].检验医学与临床,2019,16(13):1829-1831,1836.[13]王同同,郜玉峰,曹雯君,等.超敏HBV DNA检测在慢性HBV感染者中的动态监测价值[J].安徽医科大学学报,2019,54(5):785-788.[14]宋家政,刘小芹,王春蕾,等.血清免疫球蛋白检测在慢性乙型肝炎及肝硬化患者中的临床应用价值[J].肝脏,2018,23(12):1147-1148.[15]王浩,陈春晖.血清免疫球蛋白在乙型肝炎患者的临床应用价值[J].实验与检验医学,2018,36(6):895-896,905.[16]Cloherty G,Butler E,Kuhns M.Serum Hepatitis B Virus RNA as a Potential Diagnostic Biomarker During Chronic Hepatitis B Virus Infection[J].Clinical Liver Disease,2019,13(3):90-92.[17]Ergül B,Utku ZG,Yilmaz B,et al.HBeAg negative chronic hepatitis B patients with HBV-DNA levels between 2,000-20,000IU/ml and normal aminotransferases are really inactive?[J].Journal of Hepatology,2018,68(1):S504-S505.[18]马莹,姜小建,赵佳.血清免疫球蛋白检测在慢性乙型肝炎和乙肝肝硬化中的临床意义[J].现代检验医学杂志,2018,33(5):123-125.[19]鲁凤民,窦晓光,张文宏,等.慢性乙型肝炎患者血清HBV RNA检测的临床意义[J].临床肝胆病杂志,2018,34(5):934-938.[20]辛菊梅.慢性乙型肝炎及肝硬化患者HBsAg和HBV DNA定量检测的临床意义[J].临床输血与检验,2020,22(2):203-205.[21]路蔓,张静.血清免疫球蛋白在乙型肝炎患者临床检验的应用[J].中国药物与临床,2021,21(8):1382-1383.[22]杨晓婷,赖广华,卓李圆,等.血清甲状腺激素、免疫球蛋白的表达与慢性乙型肝炎的相关性研究[J].中国病案,2018,19(9):99-101.
相似文献/References:
[1]林晓岚,郑丽花,陈苑莉,等.微信随访对慢性乙型肝炎患者抗病毒治疗效果和
生活质量的影响研究[J].医学信息,2018,31(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2018,31(22):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[2]林晓岚,陈苑莉.慢性乙型肝炎患者治疗依从性及其对生活质量的影响[J].医学信息,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Journal of Medical Information,2018,31(22):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[3]陈 欢,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者
肝功能及血脂水平分析[J].医学信息,2019,32(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute,
Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Journal of Medical Information,2019,32(22):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
[4]吴 刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义[J].医学信息,2018,31(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Journal of Medical Information,2018,31(22):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[5]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Journal of Medical Information,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[6]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,32(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Journal of Medical Information,2019,32(22):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[7]钱熠辉,彭 琼.乙型肝炎病毒感染与结直肠腺瘤的相关性研究[J].医学信息,2019,32(04):81.[doi:10.3969/j.issn.1006-1959.2019.04.027]
QIAN Yi-hui,PENG Qiong.Correlation between Hepatitis B Virus Infection and Colorectal Adenoma[J].Journal of Medical Information,2019,32(22):81.[doi:10.3969/j.issn.1006-1959.2019.04.027]
[8]傅 蕊,李士欣,周国强,等.床旁超声预测慢性乙型肝炎患者胃镜检查围麻醉期误吸风险的临床价值[J].医学信息,2019,32(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2019,32(22):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[9]张媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的临床特点[J].医学信息,2019,32(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2019,32(22):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[10]罗 丹,梁惠卿,吴耀南.吴耀南教授基于“伏邪”理论治疗慢性乙肝的验案举隅[J].医学信息,2019,32(19):158.[doi:10.3969/j.issn.1006-1959.2019.19.052]
[11]朱 昕,熊 丹.不同模式乙肝五项与HBV-DNA定量及ALT的关系研究[J].医学信息,2020,33(19):162.[doi:10.3969/j.issn.1006-1959.2020.19.052]
ZHU Xin,XIONG Dan.Study on the Relationship Between Five Hepatitis B Items in Different Models, HBV-DNA Quantification and ALT[J].Journal of Medical Information,2020,33(22):162.[doi:10.3969/j.issn.1006-1959.2020.19.052]